Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT04297332Terminated
Randomised, single-blind trial (4 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Change in Delay Discounting Rate at 12 weeks and Latency to Relapse at 12 weeks. Started Jan 2020; status: terminated.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT04297332.